Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | TK1 | P04183 | 8/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.34 |
| ▸ | TK2 | O00142 | 7/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21808098 | 1.00 | CYP2C9 (0.37) | CYP2C9ALOX15TSHRCYP2C19KIF11 | |
| SCHEMBL21807990 | 0.79 | ELANE (0.36) | CYP2C9ALOX15TSHRCYP2C19KIF11 | |
| SCHEMBL9621772 | 0.71 | MAOA (0.41) | CYP2C9ELANEMEN1KMT2A | |
| SCHEMBL2522162 | 0.71 | CYP2C9 (0.48) | CYP2C9ALOX15TSHRCYP2C19KIF11 | |
| SCHEMBL11540959 | 0.68 | HDAC1 (0.41) | — | |
| SCHEMBL21224705 | 0.66 | — | — | |
| SCHEMBL21808104 | 0.66 | MAPT (0.33) | DUT | |
| SCHEMBL28791230 | 0.65 | KIF11 (0.47) | CYP2C9ALOX15TSHRCYP2C19KIF11 | |
| SCHEMBL22091459 | 0.64 | KIF11 (0.39) | CYP2C9ALOX15TSHRCYP2C19KIF11 | |
| SCHEMBL2522686 | 0.64 | KIF11 (0.39) | CYP2C9ALOX15TSHRCYP2C19KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407772-B2 | Optically-active cyclopentenone derivatives | TOHOKU UNIVERSITY (JP) | 2022-08-09 | — | — | US | disclosed |
| US-20210300953-A1 | OPTICALLY-ACTIVE CYCLOPENTENONE DERIVATIVES | TOHOKU UNIVERSITY (JP) | 2021-09-30 | — | — | US | disclosed |
| WO-2020059646-A1 | OPTICALLY-ACTIVE CYCLOPENTENONE DERIVATIVES | 国立大学法人東北大学 | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300953-A1 | OPTICALLY-ACTIVE CYCLOPENTENONE DERIVATIVES | PTGIS, PTGES, PTGES2 | CYP2C9 251/4885ALOX15 15/4885TSHR 4476/4885 |
| US-11407772-B2 | Optically-active cyclopentenone derivatives | PTGIS, PTGES, PTGES2 | CYP2C9 251/4885ALOX15 15/4885TSHR 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.